Rani Therapeutics Holdings, Inc.
RANI
$1.05
-$0.05-4.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.63M | 1.20M | 1.20M | 1.20M | 1.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.63M | 1.20M | 1.20M | 1.20M | 1.03M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.63M | 1.20M | 1.20M | 1.20M | 1.03M |
| SG&A Expenses | 19.74M | 20.11M | 21.70M | 23.11M | 23.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.94M | 42.22M | 46.76M | 48.78M | 50.63M |
| Operating Income | -38.31M | -41.02M | -45.56M | -47.58M | -49.60M |
| Income Before Tax | -40.95M | -47.60M | -52.41M | -54.54M | -56.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.95 | -47.60 | -52.41 | -54.54 | -56.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 11.28M | 19.28M | 22.72M | 24.74M | 26.57M |
| Net Income | -29.67M | -28.32M | -29.69M | -29.80M | -30.02M |
| EBIT | -38.31M | -41.02M | -45.56M | -47.58M | -49.60M |
| EBITDA | -37.41M | -40.04M | -44.55M | -46.55M | -48.57M |
| EPS Basic | -0.59 | -0.79 | -0.91 | -0.98 | -1.06 |
| Normalized Basic EPS | -0.24 | -0.22 | -0.23 | -0.23 | -0.24 |
| EPS Diluted | -0.66 | -0.79 | -0.91 | -0.98 | -1.06 |
| Normalized Diluted EPS | -0.24 | -0.22 | -0.23 | -0.23 | -0.24 |
| Average Basic Shares Outstanding | 263.52M | 149.09M | 131.48M | 121.26M | 113.85M |
| Average Diluted Shares Outstanding | 263.52M | 149.09M | 131.48M | 121.26M | 113.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |